UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases Shares of 32,678 Harrow, Inc. (NASDAQ:HROW)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Harrow, Inc. (NASDAQ:HROW) during the 3rd quarter, HoldingsChannel.com reports. The fund acquired 32,678 shares of the company’s stock, valued at approximately $1,469,000.

A number of other large investors have also made changes to their positions in the stock. First Turn Management LLC bought a new position in Harrow during the third quarter valued at about $14,683,000. Assenagon Asset Management S.A. acquired a new stake in Harrow during the third quarter worth $8,572,000. Charles Schwab Investment Management Inc. increased its holdings in Harrow by 195.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock valued at $11,313,000 after buying an additional 166,602 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Harrow in the 3rd quarter valued at $5,864,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Harrow during the 2nd quarter worth about $1,698,000. Institutional investors and hedge funds own 72.76% of the company’s stock.

Harrow Trading Up 3.2 %

HROW stock opened at $36.64 on Tuesday. The business has a fifty day moving average price of $46.12 and a 200 day moving average price of $36.18. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. Harrow, Inc. has a fifty-two week low of $9.13 and a fifty-two week high of $59.23. The stock has a market capitalization of $1.31 billion, a price-to-earnings ratio of -38.98 and a beta of 0.69.

Analysts Set New Price Targets

Several research analysts recently issued reports on HROW shares. B. Riley dropped their price target on shares of Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a research report on Wednesday, December 4th. Lake Street Capital upped their price target on Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, October 4th. Finally, Craig Hallum increased their target price on shares of Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a research report on Friday, October 4th.

Harrow Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.